Nasdaq GlobeNewswire

IPsoft Launches Amelia Healthcare Practice to Transform the Healthcare Workforce and Patient Experience with Cognitive AI

Del

NEW YORK, Sept. 26, 2017 (GLOBE NEWSWIRE) -- IPsoft, the leading digital labor company, is to launch a vertically focused portfolio of solutions for the healthcare industry based on its AI platform, Amelia. A series of Amelia Health Agent offerings are under development in a program of co-collaboration with healthcare providers, health systems, health insurers and life sciences organizations. The first releases will target high volume processes and interactions that will deliver tangible improvements for providers, insurers, carers and patients. 

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/04fe91f2-5d18-475f-b43e-7d1183aaba1b

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4758c05a-915d-4278-8f55-6ed323f7649f

A video accompanying this announcement is available at 
http://www.globenewswire.com/NewsRoom/AttachmentNg/1be90122-0c3d-499e-9a10-80da9d5262b5

The new practice builds on the positive results of Amelia implementations across industries to target the healthcare AI market, which is expected to reach $6.6 billion by 20211. 

"We have seen the hype about AI's ability to find cures for major diseases overnight.  Now it is time to recover AI's reputation by applying advanced cognitive technology to the daily operations of the sector in order to provide demonstrable benefits to patients and the organizations who treat them," said Chetan Dube, IPsoft President and CEO.  

In order to develop and lead this new global practice, IPsoft has appointed David Champeaux as its global Cognitive Director, Healthcare Solutions. David has deep experience in designing and leading technology-enabled transformations within the healthcare sector both in his previous role as a Partner in McKinsey & Company's Healthcare practice and McKinsey Digital, where he served clients in Europe, Australia and the US, and as Managing Director leading Accenture's UK Healthcare Strategy practice.

"Routine cognitive processes can take up to 51% of a nurse's and 17% of a doctor's time - which is frustrating when Health Systems struggle with affordability and workforce shortages and patients complain about access. With Amelia's unique combination of human-like conversational intelligence, advanced analytics and dynamic processes execution, we finally have the opportunity to transform healthcare by freeing up its human capital - addressing challenges in access, quality, and efficiency," said David Champeaux.

In hospitals, Amelia can have significant and immediate impact relieving those who should be caring for patients from routine interactions, by helping manage operational and administrative processes such as booking rooms and beds or coordinating patient transfers.

For chronic conditions, which account for 86%2 of healthcare spend in the US, Amelia can help health institutions establish sustainable delivery at scale of proactive, coordinated patient care plans. For example, she can streamline most administrative and operational arrangements, such as providing information, booking regular appointments and scheduling tests.

For health insurers, Amelia can help improve the customer experience and efficiency of routine member services. Amelia can deliver affordable 24/7 availability to answer eligibility and coverage questions, or initiate and manage claims. In parallel, by employing Amelia, health insurance providers will be able to connect back-end underwriting systems and processes to every customer conversation, delivering instant scale to their operations.

Amelia is the most human and comprehensive AI platform on the market. Uniquely, Amelia connects conversations to data and processes in order to provide a personalized service to every customer, at scale. Across the US, Europe and Asia, global organizations are employing Amelia to improve customer experience and drive enhanced productivity.

To learn more about how Amelia can transform business operations and customer interactions, visit ipsoft.com/amelia

About IPsoft
IPsoft automates IT and business processes for enterprises across a wide range of industries through the use of digital labor. Through its portfolio of world leading autonomic and cognitive solutions it provides services that allow its clients to secure competitive advantage. Headquartered in New York City, IPsoft has offices in 18 countries across the world and serves more than 500 of the world's leading companies directly as well as more than half of the world's largest IT services providers. To learn more about IPsoft's solutions please visit www.ipsoft.com.

Contacts

IPsoft
Daniela Zuin, 212-708-5521
Mobile: 917-822-0484
daniela.zuin@ipsoft.com
or
Finn Partners for IPsoft
Erica McDonald, 646-202-9784
Mobile: 732-713-2354
Erica.mcdonald@finnpartners.com

Frost & Sullivan, Artificial Intelligence & Cognitive Computing Systems in Healthcare

2 Centers for Disease Control and Prevention (CDC) Website Data




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IPsoft via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Nitinat Appoints John A. Gould as its Qualified Person for its Carscallen Gold Property19.2.2018 22:30Pressemelding

TORONTO, Feb. 19, 2018 (GLOBE NEWSWIRE) -- Nitinat Minerals Corporation (TSX VENTURE:NZZ) (FRANKFURT:04U1) (the "Corporation") is pleased to announce that Mr. John Alan Gould has been appointed the Qualified Person in respect of the Corporation's Carscallen Gold Property (the "Property"). Mr. Gould, who has extensive experience with geological formations similar to those found on the Property, has completed a review of the Property and has developed an initial work program. Mr. Gould, who is 60 years old and a citizen of South Africa, holds a B.Sc. degree (Geology, Physics and Chemistry) from the University of Witwatersrand. At the start of Mr. Gould's career, he was initially involved in Witwatersrand and Bushveld-type mining operations in South Africa. His experience includes all aspects of mining and geological aspects that extended over deep and shallow level gold mining operations (Venterspost, East Driefontein, Randfontein Estates, Joel Gold Mine, ERPM, Grootvlei Gold Mine, Harmo

Standard Lithium Announces Closing of $21.6 million Bought Deal Private Placement of Units16.2.2018 19:25Pressemelding

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSX-V:SLL) (OTCQX:STLHF) (FRA:S5L) announced today that it has closed its previously announced bought deal private placement of 10,312,821 units of the Company (the "Units"), at a price of $2.10 per Unit, for aggregate gross proceeds to the Company of $21,656,924, including the issuance and sale of the Underwriters' (as defined below) option (the "Offering"). Each Unit consists of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant"). Each Warrant is exercisable to acquire one common share of the Company (a "Warrant Share") until February 16, 2020 at an exercise price of $2.60 per Warrant Share, subject to adjus

Cisco Offers Cloud-Based Endpoint Security Solutions for Managed Security Service Providers16.2.2018 14:00Pressemelding

Cisco's comprehensive cloud-based security endpoint portfolio provides advanced malware protection, internet security, and enterprise mobility management SAN JOSE, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Cisco today is helping address the challenges of Managed Security Service Providers (MSSP) and their customers by offering MSSPs comprehensive security, visibility, and control of customer endpoints without added hardware or complexity. The Cisco endpoint security portfolio includes three industry-leading solutions-Cisco AMP for Endpoints, Cisco Umbrella, and Meraki Systems Manager to offer protection against advanced malware and threats. Security teams know the endpoints in their environments are being targeted by advanced threats, but often lack the security talent, tools, and budget to address those challenges. As a result, organizations of all sizes are choosing to augment their in-house IT security with managed security services. Nearly half of SMBs and enterprises in the US1 ar

Aurora Solar Adds Heterojunction Cell Characterization to Decima Gemini Family16.2.2018 14:00Pressemelding

Aurora Solar Technologies Inc. / Aurora Solar Adds Heterojunction Cell Characterization to Decima Gemini Family . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. NORTH VANCOUVER, British Columbia, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Aurora Solar Technologies Inc. ("Aurora") ("Company") (TSX.V:ACU) (OTCBB:AACTF) (FSE:A82) is pleased to provide an update on the further development of its Decima Gemini(TM) infrared measurement technology for applications in the rapidly developing heterojunction (HJT) cell manufacturing market. HJT is an ultra high-efficiency solar cell design pioneered by Japan's Panasonic Corp., who is now also partnered with Tesla Inc. for solar products. According to Solar Media Ltd., HJT production capacity is expected to increase by 20 percent this year. To produce the electrical structure of a HJT cell, it is necessary to apply thin layers of amorphous silicon on both sides of a crystallin

Nasdaq Cited as a Leader in Governance, Risk, and Compliance Platforms by Independent Research Firm16.2.2018 13:35Pressemelding

NEW YORK, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) was among the select companies that Forrester invited to participate in its 2018 Forrester Wave(TM) evaluation, Governance, Risk, And Compliance (GRC) Platforms, Q1 2018. In this evaluation, Nasdaq was cited as a Leader in Governance, Risk, and Compliance Platforms and received the maximum score of 5 for the evaluation criteria "Risk & Control Management", "Audit Management", "Dashboard and Reporting" and "Integration capabilities" for its BWise solutions. "We feel the strong scores we obtained in important functional areas provide assurance to our clients that they have selected a robust and future-proof software platform," said Tom Passon, Head of Product Innovation & Global Standards, Nasdaq BWise. "We are proud of this recognition that encourages us to further execute on our strategy to provide user-friendly, pre-configured best practice solutions that combine our innovative GRC software platform with leading expertis

Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros(TM)16.2.2018 13:00Pressemelding

Company Evaluating Deficiencies and Potential Path Forward SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the U.S. Food and Drug Administration ("FDA") has issued a complete response letter ("CRL") for the New Drug Application ("NDA") of Vitaros(TM) (alprostadil, DDAIP.HCl), a topical cream for the treatment of erectile dysfunction. The CRL indicates that the FDA cannot approve the NDA for Vitaros in its present form, identifying deficiencies related to Chemistry, Manufacturing and Control ("CMC") and certain safety concerns specific to the 2.5% concentration of DDAIP.HCl contained in the current formulation. "We are disappointed with the outcome of the review given the substantial amount of CMC, clinical and non-clinical data and analysis provided to the FDA in the Vitaros resubmission. We are assessing the content of the complete response

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom